Lachlan Hanbury Brown
Stock Analyst at William Blair
(2.94)
# 2,629
Out of 4,423 analysts
112
Total ratings
42.7%
Success rate
3.3%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Lachlan Hanbury Brown
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OCUL Ocular Therapeutix | Maintained: Buy | n/a | $9.43 | - | 16 | Jun 18, 2026 | |
| HROW Harrow | Maintained: Buy | n/a | $42.87 | - | 16 | Jun 10, 2026 | |
| TARS Tarsus Pharmaceuticals | Maintained: Buy | n/a | $63.16 | - | 11 | Jun 3, 2026 | |
| SPRY ARS Pharmaceuticals | Maintained: Buy | n/a | $9.65 | - | 25 | Jun 1, 2026 | |
| TSX: EPRX Eupraxia Pharmaceuticals Inc. | Maintained: Buy | n/a | $9.03 | - | 4 | May 13, 2026 | |
| KLRS Kalaris Therapeutics | Maintained: Buy | n/a | $4.72 | - | 11 | May 12, 2026 | |
| LENZ LENZ Therapeutics | Maintained: Buy | n/a | $6.15 | - | 17 | May 12, 2026 | |
| VRDN Viridian Therapeutics | Maintained: Buy | n/a | $16.63 | - | 8 | May 5, 2026 | |
| SLDB Solid Biosciences | Maintained: Buy | n/a | $8.33 | - | 2 | Mar 20, 2026 | |
| ZVRA Zevra Therapeutics | Maintained: Buy | n/a | $12.90 | - | 2 | Mar 16, 2026 |
Ocular Therapeutix
Jun 18, 2026
Maintained: Buy
Price Target: n/a
Current: $9.43
Upside: -
Harrow
Jun 10, 2026
Maintained: Buy
Price Target: n/a
Current: $42.87
Upside: -
Tarsus Pharmaceuticals
Jun 3, 2026
Maintained: Buy
Price Target: n/a
Current: $63.16
Upside: -
ARS Pharmaceuticals
Jun 1, 2026
Maintained: Buy
Price Target: n/a
Current: $9.65
Upside: -
Eupraxia Pharmaceuticals Inc.
May 13, 2026
Maintained: Buy
Price Target: n/a
Current: $9.03
Upside: -
Kalaris Therapeutics
May 12, 2026
Maintained: Buy
Price Target: n/a
Current: $4.72
Upside: -
LENZ Therapeutics
May 12, 2026
Maintained: Buy
Price Target: n/a
Current: $6.15
Upside: -
Viridian Therapeutics
May 5, 2026
Maintained: Buy
Price Target: n/a
Current: $16.63
Upside: -
Solid Biosciences
Mar 20, 2026
Maintained: Buy
Price Target: n/a
Current: $8.33
Upside: -
Zevra Therapeutics
Mar 16, 2026
Maintained: Buy
Price Target: n/a
Current: $12.90
Upside: -